Pediatrix Medical Group (NYSE:MD) Hits New 1-Year High – Time to Buy?

Pediatrix Medical Group, Inc. (NYSE:MD) hit a new 52-week high during trading on Monday . The stock traded as high as $26.88 and last traded at $26.9450, with a volume of 780722 shares traded. The stock had previously closed at $26.76.

Analyst Ratings Changes

MD has been the subject of several research reports. Mizuho set a $24.00 price objective on Pediatrix Medical Group in a research report on Friday, May 8th. Truist Financial boosted their target price on shares of Pediatrix Medical Group from $21.00 to $23.00 and gave the stock a “hold” rating in a research report on Monday, April 13th. Jefferies Financial Group reiterated a “buy” rating and set a $27.00 target price on shares of Pediatrix Medical Group in a research note on Monday, April 20th. UBS Group increased their price target on shares of Pediatrix Medical Group from $22.00 to $25.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $22.50.

Pediatrix Medical Group Price Performance

The stock has a market cap of $2.23 billion, a P/E ratio of 13.19 and a beta of 0.66. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.45. The company’s fifty day simple moving average is $23.19 and its 200-day simple moving average is $21.88.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The company had revenue of $476.20 million during the quarter, compared to the consensus estimate of $465.83 million. Pediatrix Medical Group had a net margin of 9.02% and a return on equity of 19.94%. The firm’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period last year, the firm earned $0.33 EPS. As a group, sell-side analysts forecast that Pediatrix Medical Group, Inc. will post 2.1 EPS for the current year.

Insider Buying and Selling

In other Pediatrix Medical Group news, Director Shirley A. Weis sold 36,028 shares of Pediatrix Medical Group stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $23.75, for a total transaction of $855,665.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Pediatrix Medical Group

A number of large investors have recently bought and sold shares of the stock. Pacer Advisors Inc. lifted its holdings in shares of Pediatrix Medical Group by 2.5% during the first quarter. Pacer Advisors Inc. now owns 506,757 shares of the company’s stock valued at $10,840,000 after acquiring an additional 12,376 shares during the period. Amundi increased its position in shares of Pediatrix Medical Group by 8.3% during the 1st quarter. Amundi now owns 15,744 shares of the company’s stock worth $337,000 after purchasing an additional 1,209 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Pediatrix Medical Group by 77.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 2,515 shares of the company’s stock worth $54,000 after purchasing an additional 1,100 shares in the last quarter. Quantinno Capital Management LP lifted its holdings in Pediatrix Medical Group by 23.4% during the 1st quarter. Quantinno Capital Management LP now owns 22,928 shares of the company’s stock valued at $490,000 after purchasing an additional 4,343 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its holdings in Pediatrix Medical Group by 22.1% during the 1st quarter. Lazard Asset Management LLC now owns 168,979 shares of the company’s stock valued at $3,614,000 after purchasing an additional 30,621 shares during the last quarter. 97.71% of the stock is currently owned by institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.